LIVA-HEALTHCARE
4.3.2021 08:02:04 CET | Business Wire | Press release
A leading provider of scalable digital health coaching in Europe, Liva Healthcare (“Liva”), launches new Scientific Advisory Board. Liva has attracted some of Europe’s most respected scientific leaders within chronic conditions and behaviour change psychology to join its global Advisory Board. The board will oversee the medical quality of the programmes and conduct the latest scientific research into Liva’s behavioural change model.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005646/en/
Liva is a health tech company that improve the lives of people at risk of, or living with, chronic conditions such as type 2 diabetes, obesity, and cardiovascular diseases by driving positive behavioural change. Liva recently announced a new funding round of EUR 24.5 million with the aim to expand its European operations. The Liva programmes are used by leading players in public healthcare, insurance and life science industries globally.
Through an app, Liva provides personal human coaching programmes to help people manage their condition and develop healthier habits that last. Liva’s combination of scalable health coaching focused on personal human relationships, with an intuitive and user-friendly interface, has proven to drive substantial clinical outcomes, and is particularly effective among traditionally hard to reach socio-economic groups.
Users on the programme living with obesity have an average sustained weight loss of 6,8kg during the first 9 months, 85% of users at high risk of developing type 2 diabetes reduce their HbA1c levels in 6 months, and 44% of users living with type 2 diabetes normalise their HbA1c level and achieve ‘control’ of their condition after 12 months on the programme (HbA1c level gets below 48 mmol/mol (6,5%).
The Advisory Board will be chaired by Liva’s Chief Medical Officer, MD, PhD, Carl J. Brandt, Postdoctoral researcher at the Research Unit for General Practice, University of Southern Denmark.
“We are proud to present a global Advisory Board of this calibre. With this board, Liva has managed to attract some of Europe’s top scientific leaders to oversee the medical and ethical quality of the Liva programmes, give input on study scope and design, and oversee the evidence-based nature of the Liva programmes,” says Dr. Brandt. “We have gathered multiple competences within our therapeutic and technological areas to guide decision-making and ensure science and research is the foundation for everything we do,” adds Dr. Brandt.
Joining Liva’s Advisory Board is Prof. Dr Lisette Van Gemert-Pijnen, Chair of Persuasive Health Technology at university of Twente, and Head of Centre for eHealth & Wellbeing Research.
“In our research at university of Twente and the Centre for eHealth & Wellbeing Research, we study how persuasive health technology can be applied to increase self-management of long-term chronic diseases, like diabetes,” says Prof. Gemert-Pijnen. “Liva Healthcare has demonstrated impressive proven clinical outcomes in chronic disease prevention and management, especially within obesity, prediabetes and type 2 diabetes, and that is why I have decided to join the Advisory Board.”
“I have been conducting research on the Dutch COVID-19 contact tracing app: CoronaMelder, and COVID-19 has taught us the importance of user-friendly, reliable and inclusive digital health tools. Generally, there has been a shift in acceptance of remote healthcare, and the need for credible digital solutions is now greater than ever. Fortunately, the Liva programmes have demonstrated how effective personalised, remote health solutions can be, and I am delighted to take a seat in this highly competent Advisory Board,” adds Prof. Gemert-Pijnen.
Additional Advisory Board members include:
- Prof. Timothy Skinner, Director of University department of Rural Health at La Trobe University, and Professor of Health Psychology at University of Copenhagen. Prof. Skinner has been responsible for developing several diabetes self-management support programmes, including DESMOND, the longest standing NHS training course for people with type 2 diabetes.
- Prof. Thorsten Lewalter, Head of Department of Cardiology, int. Klinikum München Süd, and Director of Department of Cardiology, Peter Osypka Heart Center. Prof. Lewalter is a renowned cardiology expert. He is co-editor of numerous professional journals and is considered one of the founders of modern therapy of cardiac arrhythmias.
- Stephanie Kaiser, Founder and Managing Director of the digital health platform Heartbeat Labs. Kaiser has more than 12 years’ experience in building and developing digital, consumer-oriented products. Since 2018, Kaiser has been a member of the Digital Council that advises the chancellor of Germany and the German government on the important matter of digitalisation.
- Prof. Åke Sjöholm, Associate Professor of Medicine at University of Gävle, Associate Professor at Karolinska Institute, Professor of University of South Alabama, and Associate Professor Diabetes at Region Gävleborg. Prof. Sjöholm is a prominent Swedish diabetes expert and has been listed as a noteworthy diabetes researcher by Marquis Who's Who.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005646/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
